Your shopping cart is currently empty

ML-SA1 (Mucolipin synthetic agonist 1) is a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively[1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $31 | In Stock | In Stock | |
| 5 mg | $47 | In Stock | In Stock | |
| 10 mg | $74 | In Stock | In Stock | |
| 25 mg | $153 | In Stock | In Stock | |
| 50 mg | $256 | In Stock | In Stock | |
| 100 mg | $383 | In Stock | In Stock | |
| 200 mg | $578 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $53 | In Stock | In Stock |
| Description | ML-SA1 (Mucolipin synthetic agonist 1) is a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively[1]. |
| Targets&IC50 | ZIKV:52.99 μM (IC50), DENV-2:8.3 μM (IC50) |
| In vitro | ML-SA1 (25 μM; 0~14 hours; A549 cells) potentially affects the entry of DENV2 into host cells[1]. ML-SA1 (0~200 μM; A549 cells) shows no cytotoxicity at concentrations up to 200 μM. It significantly suppresses DENV2 RNA levels with an IC50 of 8.93 μM[1]. ML-SA1 also reduces ZIKV RNA and protein levels in a dose-dependent manner, with an IC50 of 52.99 μM against ZIKV RNA. As an activator of TRPMLs, ML-SA1 is a potent inhibitor of DENV2 and ZIKV in vitro, promoting lysosomal acidification and protease activity to inhibit viral infection, and can induce autophagy in Huh7 or A549 cells[1]. |
| Synonyms | Mucolipin synthetic agonist 1 |
| Molecular Weight | 362.42 |
| Formula | C22H22N2O3 |
| Cas No. | 332382-54-4 |
| Smiles | CC1CC(C)(C)N(C(=O)CN2C(=O)C3=CC=CC=C3C2=O)C2=C1C=CC=C2 |
| Relative Density. | 1.226 g/cm3 (Predicted) |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 17 mg/mL (46.91 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.52 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.